OncoMatch/Clinical Trials/NCT05468242
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
Is NCT05468242 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant chemo-immunotherapy and Bevacizumab for stage iii non-small cell lung cancer.
Treatment: Neoadjuvant chemo-immunotherapy · Bevacizumab · Tislelizumab — The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Performance status
WHO 0–1
Prior therapy
Cannot have received: chemotherapy
Without prior chemotherapy
Cannot have received: radiotherapy
Without prior radiotherapy
Cannot have received: surgery
Without prior surgery
Cannot have received: targeted therapy
Without prior targeted therapy
Cannot have received: immunotherapy
Without prior immunotherapy
Cannot have received: anti-PD-1 therapy
Prior exposure to any anti-programmed cell death protein(PD)-1 or anti-PD-L1 antibody
Lab requirements
Blood counts
Absolute neutrophil count >1.5 x 10^9/L (1500 per mm3); Platelets >100 x 10^9/L (100,000 per mm3); Haemoglobin≥9.0 g/dL (5.59 mmol/L)
Kidney function
Serum creatinine clearance(CL) >50 mL/min by the Cockcroft-Gault formula
Liver function
Serum bilirubin ≤1.5 x upper limit of normal (ULN). Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤2.5 x ULN
Absolute neutrophil count >1.5 x 10^9/L (1500 per mm3); Platelets >100 x 10^9/L (100,000 per mm3); Haemoglobin≥9.0 g/dL (5.59 mmol/L); Serum creatinine clearance(CL) >50 mL/min by the Cockcroft-Gault formula; Serum bilirubin ≤1.5 x upper limit of normal (ULN). Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify